BioGaia (BIOG) Q3 2025 earnings summary

Executive summary

• Q3 sales reached SEK 327 million, up 7% year-over-year, with 14% organic growth excluding currency effects, driven by strong performance in Americas (+10%) and APAC (+17%), and increased media investments in key direct markets.

• EBIT for Q3 rose to SEK 86 million, a 108% increase, with EBIT margin improving to 26% from 14% last year.

• Record sales achieved in the US and France, with new product launches and expansion into direct markets such as Australia, France, Germany, and Austria.

• Direct markets now represent 36% of total sales for the quarter.

• Strategic focus remains on core health segments, direct market expansion, and breakthrough innovation.

Financial highlights

• Gross margin improved to 74% from 73% year-over-year, mainly due to favorable geographic mix and price increases.

• Cash flow from operating activities was SEK 110 million, with period-end cash at SEK 728 million.

• Total expenses were SEK 157 million, down 13% year-over-year; sales and marketing costs rose 21%.

• Profit after tax for Q3 was SEK 66 million, up 80% year-over-year; EPS rose to SEK 0.65.

• YTD operating profit down 9% to SEK 291.5 million, margin at 27%.

Outlook and guidance

• Continued investment in direct markets (France, Germany, U.S., Canada, Austria) expected to drive future growth.

• Anticipates temporary sales declines in new direct markets as partners sell through inventory, followed by growth.

• Ambition to improve EBIT margin toward 34% target, with OpEx growth expected to lag gross profit growth.

• Dividend policy: 50% of profit after tax, with potential extra dividends of 50–100% of profit after tax, excluding non-recurring items.